China DealBook
A Newsletter on Deal Making in China

By: ChinaDesk | May 21, 2017

A Newsletter on Deal Making in China | M&A . Investment Banking .VC . PE . Deals

stada_shanghai_pharma_china_dealbook_m&a_news

Deal News


Shanghai Pharma weighs rival bid for Germany's Stada
Shanghai Pharmaceutical Holding Co Ltd said it may bid for Stada Arzneimittel AG - a move that would pit it against buyout firms Bain and Cinven which have made a joint offer of nearly $6 billion for the German generics drugmaker.

The Chinese company said in a filing it had recently discussed the matter with "a couple of financial investors" but added it had not made a concrete offer and there were still many uncertainties. Shanghai Pharma, which has a market value of $9 billion, needs to submit its bid by June 8 if it wants to challenge an existing 66 euro-a-share bid by Bain and ...

By: ChinaDesk | May 14, 2017

A Newsletter on Deal Making in China | M&A . Investment Banking .VC . PE . Deals

china_deals_2017_m&a_news_newsletter

Deal News


China's $246 Billion Foreign Buying Spree Is Unraveling
After stunning the world with a record $246 billion of announced outbound takeovers in 2016, Chinese dealmakers are now struggling to cope with tighter capital controls and increasingly wary counterparties. Cross-border purchases plunged 67 percent during the first four months of this year, the biggest drop for a comparable period since the depths of the global financial crisis in 2009.


Andre Loesekrug-Pietri, founder and managing partner of A Capital, a private equity fund specializing in Chinese outbound investments, doubts if 2017 could match the $170 billion worth of Chinese investments m...

By: ChinaDesk | April 13, 2017

A Newsletter on Deal Making in China | M&A . Investment Banking .VC . PE . Deals

xPerception_baidu_ai_acquisition_china_m&a_dealbook_news

Deal News


China's Baidu buys U.S. computer vision startup amid AI push
Chinese internet firm Baidu Inc has agreed to acquire U.S. computer vision firm xPerception for an undisclosed amount to support their renewed efforts in artificial intelligence as Chinese tech firms face regulatory headwinds in U.S.


xPerception, which makes vision perception software and hardware with applications in robotics and virtual reality, is founded by two former engineers from Magic Leap, a U.S. augmented reality startup.


China-backed fund to acquire Xcerra for $580 million
Sino IC Capital, a technology-focused private equity fund manager backed by the Chinese government h...

By: ChinaDesk | April 03, 2017

A Newsletter on Deal Making in China | M&A . Investment Banking .VC . PE . Deals

biotest_creat_group_china

Deal News


China's Creat makes 1.2 billion euro bid for German blood plasma firm
Chinese investor Creat Group Corp has offered to buy German blood plasma products maker Biotest for about 1.2 billion euros ($1.3 billion) including debt following its purchase last year of British peer Bio Products Laboratory.


Biotest Chief Executive Bernhard Ehmer told a news conference on Thursday that Creat had not been the only potential bidder to approach Biotest about a deal but it chose to talk to Creat because its proposal was "thought through".


HNA, Apollo Global among bidders vying for HSH Nordbank: sources
Chinese conglomerate HNA Group and Apollo Glob...

By: ChinaDesk | March 30, 2017

A Newsletter on Deal Making in China | M&A . Investment Banking .VC . PE . Deals

tencent_tesla_china_investment_newsletter_dealbook

Deal News

Tencent of China Takes 5 Percent Stake in Tesla

Chinese tech giant Tencent Holdings Ltd. has bought a 5% stake in U.S. electric vehicle maker and renewable energy firm Tesla for US$1.78 billion. This is a deal that gives investors much to anticipate as the two could potentially partner on many areas.


Tencent now holds 5% of Tesla's outstanding shares and has become the fifth-largest shareholder of the company. It joins a distinguished list of key shareholders, including CEO Elon Musk (21%) and investment firms Fidelity (14%), Baillie Gifford (8.2%), and T. Rowe Price (7.3%). Tencent's stake is very strategic, far from a mere financial play. The...

next>>